Division Details

Division Data Summary

RESEARCH AND TRAINING DETAILS

<table>
<thead>
<tr>
<th>Data Point</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Faculty</td>
<td>21</td>
</tr>
<tr>
<td>Number of Joint Appointment Faculty</td>
<td>3</td>
</tr>
<tr>
<td>Number of Support Personnel</td>
<td>30</td>
</tr>
<tr>
<td>Direct Annual Grant Support</td>
<td>$1,213,386</td>
</tr>
<tr>
<td>Direct Annual Industry Support</td>
<td>$65,623</td>
</tr>
<tr>
<td>Peer Reviewed Publications</td>
<td>21</td>
</tr>
</tbody>
</table>

CLINICAL ACTIVITIES AND TRAINING

<table>
<thead>
<tr>
<th>Data Point</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Clinical Staff</td>
<td>57</td>
</tr>
<tr>
<td>Number of Other Students</td>
<td>20</td>
</tr>
<tr>
<td>Inpatient Encounters</td>
<td>19,953</td>
</tr>
<tr>
<td>Outpatient Encounters</td>
<td>34,141</td>
</tr>
</tbody>
</table>

Significant Accomplishments

Improving Our Understanding of Aggression in Children

Drew Barzman, MD, has created a unique database of more than 3,000 individuals to conduct studies of pediatric aggression. Recent studies have explored the relationship of fMRI and salivary biomarkers with aggressive behavior and are evaluating the utilization of such measures to assist in predicting aggressive acts.

Fragile X Center Studies New Treatments

Craig Erickson, MD, established our Fragile X Research and Treatment Center in 2012 and has started several translational research projects. Erickson is using a four-year, $1 million grant from The John Merck Fund to conduct a double-blind, placebo-controlled study of acamprosate in youth with Fragile X. Our Center also has received three other industry contracts to study novel investigational drugs in youth and adults with Fragile X Syndrome.

The Fragile X Center also has started a translational treatment mouse research program under the direction of Tori Schaefer, PhD. She is using a grant from the FRAXA Research Foundation to study of a novel modulator of GABA neurotransmission in Fragile X knockout mice.

The Fragile X Center also has begun collaborating with the National Fragile X Foundation and the Centers for Disease Control and Prevention on a longitudinal behavior tracking study.

Expanding the Continuum of Care
In 2012, we opened a partial psychiatric hospitalization program at our new Green Township campus to help meet the growing need for pediatric and adolescent psychiatric care in our region.

The new program offers five to 10 days of intensive management provided by physicians, nurses, social workers, and psychologists, while allowing patients to continue residing at home. Frequent areas of treatment focus include depression, self-injury, school refusal, anxiety, and disruptive behavior.

Thanks to a generous donation from the Pichler family, our Green Township program brings our partial hospitalization capacity to about 4,000 patient days per year. Overall, increased utilization of advanced practice nurses, psychiatric social workers, and clinical counselors have increased our outpatient visits to more than 29,000 in the past fiscal year.

Research Highlights

FRAGILE X RESEARCH AND TREATMENT CENTER

Dr. Craig Erickson established the Fragile X Research and Treatment Center within the Division of Child and Adolescent Psychiatry in 2012. The center has started several new translational treatment development research projects within the last year. In 2013 Dr. Erickson received a four year one million dollar grant from The John Merck Fund to conduct a double-blind, placebo-controlled study of acamprosate in youth with Fragile X. The Fragile X Center additionally received three industry contracts to study novel investigational drugs in youth and adults with Fragile X Syndrome. The Fragile X Center has also started a translational treatment development mouse research program under the direction of Tori Schaefer, PhD. Dr. Schaefer received a grant from the FRAXA Research Foundation to conduct a study of a novel modulator of GABA neurotransmission in Fragile X knockout mice. The Fragile X Center continues to collaborate worldwide with investigators in the development of new targeted treatments for the disorder. Finally, the Fragile X program began collaboration with the National Fragile X Foundation and the United States Centers for Disease Control (CDC) on a longitudinal behavior tracking study in the disorder.

Division Publications


**Faculty, Staff, and Trainees**

**Faculty Members**

**Michael Sorter, MD,** Associate Professor  
**Leadership** Director, Division of Psychiatry

**Drew Barzman, MD,** Assistant Professor  
**Leadership** Director of Child & Adolescent Forensic Psychiatry Service

**Sandra Batsel-Thomas, MD,** Assistant Professor
Cynthia Daugherty, MD, Assistant Professor

Sergio Delgado, MD, Associate Professor
  **Leadership** Director of Outpatient Services

Carol Engel, MD, Assistant Professor
  **Leadership** Residency Training Director, Triple Board Program

Craig Erickson, MD, Assistant Professor

Elana Harris, MD, Assistant Professor

Mark Johnson, MD, Assistant Professor

Brian Kurtz, MD, Assistant Professor
  **Leadership** Director of Consultation Services

Mary Matias-Akhtar, MD, Assistant Professor

Daniel Nelson, MD, Associate Professor
  **Leadership** Director of Inpatient Services

Hilton Rodriguez, MD, Assistant Professor

Suzanne Sampang, MD, Assistant Professor
  **Leadership** Residency Training Director, Child & Adolescent Psychiatry

Raymond Troy, MD, Assistant Professor

Daniel Vogel, MD, Assistant Professor

Logan Wink, MD, Assistant Professor

Joint Appointment Faculty Members

  **Melissa DelBello, MD**, Associate Professor (Psychiatry)

  **Jeffrey Strawn, MD**, Assistant Professor (Psychiatry)

Trainees

  **Anthony Cavalieri, MD**, PGY 6, Wayne State University School of Medicine, Detroit Michigan

  **Deborah Amann, MD**, PGY 5, Wright State University, Dayton Ohio

  **Reyna Gilmore, MD**, PGY 5, Howard University College of Medicine, Washington DC

  **Deana McReynolds, MD**, PGY 4, Murray State University, Murray KY

  **John Vraciu, MD**, PGY 4, Kent State University, Kent OH

  **Courtney Cinko, MD**, PL 3, Rush Medical College, Chicago IL

  **Kelli Dominick, MD**, PL 2, Boston University School of Medicine

  **Diana Frey, MD**, PL 4, Mayo Medical School, Rochester MN

  **Delanie Janke, MD**, PL 4, University of Texas Medical Branch, Galvetton TX

  **Paul Houser, MD**, PL 3, St. Louis University School of Medicine, St. Louis MO

  **Mercedes Kwiatkowski, MD**, PL 5, Georgetown University School of Medicine

  **Ernest Pedapati, MD**, PL 4, University of Massachusetts Medical School, North Worcester MA

  **Lindsay Tobler, MD**, PL 5, University of Missouri, Columbia MO

  **Sophianne Subbiah, MD**, PL 1, University of Iowa School of Medicine, Iowa City, IA

  **Theresa Umhoefer, MD**, PL 1, University of Wisconsin
Melissa Schuman-Wagner, MD, PL 1, Medical College of Wisconsin, Milwaukee, WI
Elizabeth Wassenaar, MD, PL 5, Jefferson Medical College of Thomas Jefferson University, Philadelphia PA
Yesie Yoon, MD, PL 2, Yonsei University

Division Collaboration

**Neurology** » David Franz and Tracy Glauser
Tuberous Sclerosis Clinic, Pharmacogenetics Seizure Therapy

**Adolescent Medicine** » Frank Biro and Laurie Mitan
Mental Health Treatment Clinic in Adolescent Medicine Center and Eating Disorders

**DDBP** » Patricia Manning, Rena Sorensen, and Michael Lind
Center for School Crisis and Bereavement, Kelly O’Leary Center/Autism Treatment, Comorbid Intellectual Disability and Mental Illness Services

**Pediatric Primary Care** » Mona Mansour
Mental Health Consultation

**Behavioral Medicine and Clinical Psychology** » Lori Stark and Jeff Epstein
ADHD Consultations to Pediatricians, Outpatient Care, Inpatient Consultations

**Hematology/Oncology** » John Perentesis
Specialized Consultation Service

**Pediatric Endocrinology** » Larry Dolan and David Klein
Management of Atypical Antipsychotic/Metabolic Syndrome

**Human Genetics** » Howard Saal
Velocardio Facial Syndrome

**Mayerson Center** » Bob Shapiro
Trauma Treatment and Clinic

Grants, Contracts, and Industry Agreements

<table>
<thead>
<tr>
<th>Grant and Contract Awards</th>
<th>Annual Direct</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ERICKSON, C</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Acamprosate in Fragile X Syndrome</strong></td>
<td>01/01/13-12/31/16</td>
</tr>
<tr>
<td>The John Merck Fund</td>
<td></td>
</tr>
<tr>
<td><strong>Acamprosate in Youth with Autism Spectrum Disorder</strong></td>
<td>12/01/12-11/30/15</td>
</tr>
<tr>
<td>Autism Speaks Grant Administration</td>
<td></td>
</tr>
<tr>
<td><strong>Extracellular Signal-Related Kinase Biomarker Development in Autism</strong></td>
<td>09/01/12-08/31/14</td>
</tr>
<tr>
<td>Simons Foundation</td>
<td></td>
</tr>
<tr>
<td><strong>D-Cycloserine for Enhancement of Social Skills Training in Pervasive Development</strong></td>
<td></td>
</tr>
<tr>
<td>Department of Defense(Indiana University Health)</td>
<td></td>
</tr>
</tbody>
</table>
### Accomprosate in Youth with Autistic Disorder

The American Academy of Child and Adolescent Disorder

*7/16/2012-12/31/2012*

| W81XWH-09-1-0091 | 08/01/12-02/14/14 | $158,330 |

### KOWATCH, R

**Longitudinal Assessment of Manic Symptoms**

National Institutes of Health

R01 MH 073816 | 07/01/10-02/28/15 | $473,402 |

### SORTER, M

**Effective Trauma Detection and Treatment in School-Aged Children**

Health Foundation of Greater Cincinnati

| 04/01/13-03/31/14 | $45,000 |

### WINK, K

**A Phase II Trial of Levodopa in Angelman Syndrome**

Food and Drug Administration (Children's Hospital Boston)

R01 FD 003523 | 08/01/12-07/31/13 | $35,000 |

### Current Year Direct

| **Current Year Direct** | $1,213,386 |

### Industry Contracts

| DELGADO, S |
| Pfizer, Inc | $19,362 |

| ERICKSON, C |
| Roche Laboratories, Inc | $28,998 |
| Seaside Therapeutics, Inc | $10,010 |

| WINK, L |
| SynapDx | $7,253 |

### Current Year Direct Receipts

| **Current Year Direct Receipts** | $65,623 |

### Total

| **Total** | $1,279,009 |